AustinPx announced its agreement with Thermo Fisher Scientific’s Patheon pharma services for the installation of AustinPx’s KinetiSol™ Technology equipment.
Under the agreement, AustinPx will install KinetiSol equipment at Thermo Fisher’s Bend, Oregon, and Cincinnati, Ohio, oral solid drug manufacturing sites, extending KinetiSol capabilities from development and scale-up through commercial manufacturing. As the exclusive third-party CDMO provider offering the KinetiSol Formulator technology, Thermo Fisher will provide customers with an integrated pathway to advance KinetiSol-enabled products across the drug development lifecycle. KinetiSol is AustinPx’s solvent-free, fusion-based amorphous solid dispersion (ASD) technology designed to enhance the bioavailability of poorly soluble drugs while streamlining scalability and enabling more environmental and economic sustainability. The technology has been proven to open the formulation design space for challenging active pharmaceutical ingredients, including molecules with high melting points, poor organic solvent solubility, and heat sensitivity.
AustinPx continues to see significant interest in and utilization of KinetiSol among sponsors working with poorly soluble drug candidates that require improved bioavailability, manufacturability and sustainability. Since launching AustinPx in 2022, KinetiSol has been used by more than 70 pharmaceutical and biotech companies, including seven of the top ten large pharmas.
“This agreement marks an important milestone for AustinPx, our clients, and the growing number of molecules enabled by KinetiSol Technology,” said Elizabeth Hickman, CEO of AustinPx. “Thermo Fisher’s agreement with KinetiSol provides important external validation from an established global CDMO with deep experience in advanced formulation technologies and commercial manufacturing.”
For AustinPx’s KinetiSol clients, the agreement provides another proven route to late-stage and commercial manufacturing of their KinetiSol-enabled products. It also expands the KinetiSol ecosystem and demonstrates the technology’s commercial relevance for sponsors seeking to evaluate KinetiSol earlier as part of a long-term ASD strategy.
“At Thermo Fisher Scientific, we are committed to helping our customers accelerate the development and delivery of life-changing medicines,” said Jennifer Cannon, President, Commercial, Biopharma Services, Thermo Fisher Scientific. “The addition of KinetiSol Technology strengthens our advanced oral drug delivery capabilities and provides customers with greater flexibility as they move innovative therapies from IND approval to commercialization. This collaboration reflects our shared commitment to enabling solutions for challenging molecules and improving access to critical treatments for patients worldwide.”